(134) found that combination therapy slowed tumor growth and significantly increased survival in mice at 50 days post-load (57% in the combination group vs. 25% in the anti-CTLA-4 alone group), and reduced the number of lung metastases from an average of 30 to 1. The gene discussed is CTLA4; the disease is neoplasm.